140 related articles for article (PubMed ID: 18469483)
1. Serum concentrations of adiponectin in patients with hyperthyroidism before and after control of thyroid function.
Hsieh CJ; Wang PW
Endocr J; 2008 Jul; 55(3):489-94. PubMed ID: 18469483
[TBL] [Abstract][Full Text] [Related]
2. Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function.
Iglesias P; Alvarez Fidalgo P; Codoceo R; Díez JJ
Clin Endocrinol (Oxf); 2003 Nov; 59(5):621-9. PubMed ID: 14616887
[TBL] [Abstract][Full Text] [Related]
3. Serum leptin concentrations of patients with sequential thyroid function changes.
Hsieh CJ; Wang PW; Wang ST; Liu RT; Tung SC; Chien WY; Lu YC; Chen JF; Chen CH; Kuo MC
Clin Endocrinol (Oxf); 2002 Jul; 57(1):29-34. PubMed ID: 12100066
[TBL] [Abstract][Full Text] [Related]
4. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
[TBL] [Abstract][Full Text] [Related]
5. A patient-specific treatment model for Graves' hyperthyroidism.
Pandiyan B; Merrill SJ; Di Bari F; Antonelli A; Benvenga S
Theor Biol Med Model; 2018 Jan; 15(1):1. PubMed ID: 29310665
[TBL] [Abstract][Full Text] [Related]
6. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.
Kumeda Y; Inaba M; Tahara H; Kurioka Y; Ishikawa T; Morii H; Nishizawa Y
J Clin Endocrinol Metab; 2000 Nov; 85(11):4157-61. PubMed ID: 11095447
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for neonatal thyroid dysfunction in pregnancies complicated by Graves' disease.
Uenaka M; Tanimura K; Tairaku S; Morioka I; Ebina Y; Yamada H
Eur J Obstet Gynecol Reprod Biol; 2014 Jun; 177():89-93. PubMed ID: 24726178
[TBL] [Abstract][Full Text] [Related]
8. Hyperthyroidism is associated with higher plasma endothelin-1 concentrations.
Chu CH; Lee JK; Keng HM; Chuang MJ; Lu CC; Wang MC; Sun CC; Wei MC; Lam HC
Exp Biol Med (Maywood); 2006 Jun; 231(6):1040-3. PubMed ID: 16741045
[TBL] [Abstract][Full Text] [Related]
9. Serum leptin and ghrelin levels in premenopausal women with stable body mass index during treatment of thyroid dysfunction.
Braclik M; Marcisz C; Giebel S; Orzeł A
Thyroid; 2008 May; 18(5):545-50. PubMed ID: 18466078
[TBL] [Abstract][Full Text] [Related]
10. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
[TBL] [Abstract][Full Text] [Related]
11. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
[TBL] [Abstract][Full Text] [Related]
12. Circulating adiponectin concentrations were related to free thyroxine levels in thyroid cancer patients after thyroid hormone withdrawal.
Lin SY; Huang SC; Sheu WH
Metabolism; 2010 Feb; 59(2):195-9. PubMed ID: 19765779
[TBL] [Abstract][Full Text] [Related]
13. Physiological and Metabolic Changes During the Transition from Hyperthyroidism to Euthyroidism in Graves' Disease.
Chng CL; Lim AY; Tan HC; Kovalik JP; Tham KW; Bee YM; Lim W; Acharyya S; Lai OF; Chong MF; Yen PM
Thyroid; 2016 Oct; 26(10):1422-1430. PubMed ID: 27465032
[TBL] [Abstract][Full Text] [Related]
14. Elevation of serum adiponectin levels in Basedow disease.
Saito T; Kawano T; Saito T; Ikoma A; Namai K; Tamemoto H; Kawakami M; Ishikawa SE
Metabolism; 2005 Nov; 54(11):1461-6. PubMed ID: 16253634
[TBL] [Abstract][Full Text] [Related]
15. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
Brokken LJ; Wiersinga WM; Prummel MF
J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
[TBL] [Abstract][Full Text] [Related]
16. Relationship of thyroid function with body mass index, leptin, insulin sensitivity and adiponectin in euthyroid obese women.
Iacobellis G; Ribaudo MC; Zappaterreno A; Iannucci CV; Leonetti F
Clin Endocrinol (Oxf); 2005 Apr; 62(4):487-91. PubMed ID: 15807881
[TBL] [Abstract][Full Text] [Related]
17. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.
Yamano Y; Takamatsu J; Sakane S; Hirai K; Kuma K; Ohsawa N
Thyroid; 1999 Aug; 9(8):769-73. PubMed ID: 10482368
[TBL] [Abstract][Full Text] [Related]
18. Laboratory tests for evaluating thyroid therapy.
Kabadi UM
Am Fam Physician; 1982 Sep; 26(3):183-8. PubMed ID: 6180620
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations of adiponectin and leptin in patients with thyroid dysfunctions.
Santini F; Marsili A; Mammoli C; Valeriano R; Scartabelli G; Pelosini C; Giannetti M; Centoni R; Vitti P; Pinchera A
J Endocrinol Invest; 2004 Feb; 27(2):RC5-7. PubMed ID: 15129802
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
Maugendre D; Massart C
Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
